Could CAR-T cells tame tough autoimmune diseases?

NCT ID NCT06947473

Recruiting now Disease control Sponsor: Beijing GoBroad Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial is testing a new treatment made from umbilical cord blood cells, called CD19-BCMA CAR-T cells, in 45 people with severe lupus, scleroderma, or Sjogren's syndrome with lung complications. The main goal is to check safety, especially serious side effects within the first month. Researchers will also look at how well the disease responds over the next few months to years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: umbilical cord blood CD19-BCMA CAR-T cells
What this could lead to: If successful, this could offer a new treatment option for people with severe autoimmune diseases that haven't responded to standard therapies.
What could go wrong: This is an early-phase trial with only 45 participants, so results may not apply to everyone. There are risks of serious side effects from the chemotherapy and CAR-T cells, including cytokine release syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY SJOGREN'S SYNDROME COMBINED WITH PULMONARY HYPERTENSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lupus nephritis Sjogren syndrome systemic sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRIMARY SJOGREN'S SYNDROME COMBINED WITH PULMONARY HYPERTENSION REFRACTORY LUPUS NEPHRITIS SYSTEMIC SCLEROSIS

Contacts and locations

Locations

Beijing GoBroad Hospital
RECRUITING

Beijing, Beijing Municipality, 102206, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.